Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma

被引:105
作者
Bergsagel, PL
Kuehl, WM
机构
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1034/j.1600-065X.2003.00052.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple myeloma (MM) is a tumor of long-lived bone marrow plasma cells (PCs). Nearly 40% of MM tumors have immunoglobulin H (IgH) translocations involving four recurrent chromosomal loci (oncogenes): 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (MMSET and FGFR3), and 16q23 (c-maf). Other MM tumors have Ig translocations involving different loci, none of which is involved in more than 1% of tumors. At least 25% of MM tumors have no Ig translocation. Unlike normal PCs, MM tumors usually express one of the three cyclin D genes at a high level. Translocations involving 4p16 and 16q23 do not directly target a cyclin D gene, but they are associated with a high level of cyclin D2 expression. Although cyclin D1 is not expressed in normal hematopoietic cells, one-third of MM tumors ectopically express cyclin D1 in the absence of t(11;14). Despite a low proliferation index in MM, dysregulation of a cyclin D gene seems to be a unifying oncogenic event. Analysis of 34 MM cell lines indicates that tumors having an IgH translocation are significantly over-represented, whereas tumors that ectopically express cyclin D1 are not represented. We speculate that ectopic cyclin D1 expression without t(11;14) is dependent on tumor-specific interaction with bone marrow stromal cells.
引用
收藏
页码:96 / 104
页数:9
相关论文
共 30 条
[11]   In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression [J].
Keats, JJ ;
Reiman, T ;
Maxwell, CA ;
Taylor, BJ ;
Larratt, LM ;
Mant, MJ ;
Belch, AR ;
Pilarski, LM .
BLOOD, 2003, 101 (04) :1520-1529
[12]   Alterations of the cyclin D1/pRb/p16 INK4A pathway in multiple myeloma [J].
Krämer, AK ;
Schultheis, B ;
Bergmann, J ;
Willer, A ;
Hegenbart, U ;
Ho, AD ;
Goldschmidt, H ;
Hehlmann, R .
LEUKEMIA, 2002, 16 (09) :1844-1851
[13]   Multiple myeloma: Evolving genetic events and host interactions [J].
Kuehl, WM ;
Bergsagel, PL .
NATURE REVIEWS CANCER, 2002, 2 (03) :175-187
[14]   Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis [J].
Kulkarni, MS ;
Daggett, JL ;
Bender, TP ;
Kuehl, WM ;
Bergsagel, PL ;
Williams, ME .
LEUKEMIA, 2002, 16 (01) :127-134
[15]   Mechanisms of chromosomal translocations in B cell lymphomas [J].
Küppers, R ;
Dalla-Favera, R .
ONCOGENE, 2001, 20 (40) :5580-5594
[16]   A long-term study of prognosis in monoclonal gammopathy of undetermined significance [J].
Kyle, RA ;
Therneau, TM ;
Rajkumar, SV ;
Offord, JR ;
Larson, DR ;
Plevak, MF ;
Melton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :564-569
[17]   Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40 [J].
Lam, EWF ;
Glassford, J ;
Banerji, L ;
Thomas, NSB ;
Sicinski, P ;
Klaus, GGB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (05) :3479-3484
[18]   CYCLIN D1 BCL-1 COOPERATES WITH MYC GENES IN THE GENERATION OF B-CELL LYMPHOMA IN TRANSGENIC MICE [J].
LOVEC, H ;
GRZESCHICZEK, A ;
KOWALSKI, MB ;
MOROY, T .
EMBO JOURNAL, 1994, 13 (15) :3487-3495
[19]   Familial multiple myeloma: A family study and review of the literature [J].
Lynch, HT ;
Sanger, WG ;
Pirruccello, S ;
Quinn-Laquer, B ;
Weisenburger, DD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (19) :1479-1483
[20]   Experimental plasmacytomagenesis in mice [J].
Potter, M .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (02) :323-+